- Home
- LSF vs NNVC Comparison
LSF vs NNVC Comparison
Compare LSF & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LSF | NNVC |
|---|---|---|
| Founded | 2015 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.8M | 24.4M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | LSF | NNVC |
|---|---|---|
| Price | $3.34 | $1.06 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | 124.1K | ★ 298.0K |
| Earning Date | 02-25-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $48,146,862.00 | N/A |
| Revenue This Year | $18.05 | N/A |
| Revenue Next Year | $17.53 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 17.73 | N/A |
| 52 Week Low | $1.98 | $0.94 |
| 52 Week High | $8.26 | $2.23 |
Technical Indicators
Market Signals| Indicator | LSF | NNVC |
|---|---|---|
| Relative Strength Index (RSI) | 61.78 | 39.42 |
| Support Level | $3.07 | $1.13 |
| Resistance Level | $3.62 | $1.16 |
| Average True Range (ATR) | 0.33 | 0.06 |
| MACD | 0.07 | -0.00 |
| Stochastic Oscillator | 73.88 | 14.62 |
Price Performance
Historical ComparisonAbout LSF Laird Superfood Inc.
Laird Superfood Inc is engaged in the business of manufacturing and marketing differentiated plant-based and functional foods. The product portfolio includes Coffee creamers, Hydration products and beverage-enhancing supplements, Harvest snacks and various other food items, and Coffee, tea, and hot chocolate products.
About NNVC NanoViricides Inc.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.